Big Moves on Big Volume Could Continue
|Written by GSCR Staff|
|Wednesday, 12 December 2012 11:26|
Good morning and happy 12-12-12! As unsettling as the date may be to some, if we are right about today’s profiled stock, 12-12-12 will be a profitable day.
Telik Inc. (NASDAQ – TELK - $1.96) is a California-based clinical stage drug development company focused on various forms of cancer treatment with a solid management team consisting of several Ph.D. and M.D. leaders, each having many years of experience in the industry. The Company has 2 products in Phase 2 clinical trials and a number of preclinical problems.
GST P1-1 ROLE IN CANCER: A variety of human cancers, including breast, colon, kidney, lung and ovarian, usually express high levels of GST P1-1 compared to the surrounding tissues. High expression of GST P1-1 has been associated with disease progression and with drug resistance in patients undergoing chemotherapy. This is the basis for much of the drug discovery for the Company.
TELINTRA® (Ezatiostat HCl): A small molecule bone marrow stimulant that is in a Phase 2 trial in myelodysplastic syndrome (MDS) and severe chronic idiopathic neutropenia (SCN). TELCYTA®: (Canfosfamide HCl): A cancer cell-activated small molecule that is in development for ovarian and non-small cell lung cancer. Learn more about TELCYTA®
Additionally, Telik has developed a proprietary development platform called TRAP, which is a revolutionary small molecule screening process. TRAP allows Telik to screen approximately 10,000 times less compounds used in identifying disease related targets. This technology is being used in additional projects in the pipeline, and could rapidly increase development time.
The Bottom Line
The stock has been a dog this year after completing a 1:30 reverse stock split. Management has been forced to reduce headcount and other expenses, and according to the 3Q12 results release, it appears as if the Company needs additional funding to pay for clinical development past 1Q13. Sounds like a reason to avoid the stock, right?
Well, there was very heavy volume on Monday with nearly 1 million shares traded and the stock jumping as much as 64%, intraday. Typically, the stock trades in the tens of thousands of shares. Big volume continued yesterday and continues today. We should note that the 52-week range on the stock is $9.00 - $1.09, so it remains near the lows for the year, despite the big moves.
We do not believe that the recent big swings are illustrative of a dead cat bounce.
Instead, since the stock is under real accumulation, we are speculating that Telik is close to obtaining financing, which would sharply reduce the risk inherent in these shares. While equity financing is usually a dilutive driver of stock price, there was a recent transaction in the pharmaceutical sector that shows a quick pop is possible. Acadia Pharmaceuticals announced a deal worth $86 million at the close yesterday with the stock at $4.43. It hit $5.18 already today! With all these factors in play we like TELK for a pop to the $3.00 level if our hunch is correct.
Disclosure: The authors of this blog are neither long nor short these shares but may elect to purchase the stock within the next 48 hours.
This Market Monitor blog was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research, which typically highlights small cap companies, and Goldman Opportunity Research, which features micro cap companies in a sponsored research format. Thus, the Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports.
It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in each company-specific report. All information contained in this blog, newsletter and in our reports were provided by the Companies or generated from our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research blog, report, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This blog does not take into account the investment objectives, financial situation, or particular needs of any particular person. This blog does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA or with any state securities regulatory authority.
ALL INFORMATION IN THIS BLOG, REPORT OR NEWSLETTER IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com
Leave your comments